Wichtige Punkte
- 3D printing enables on‑demand, highly personalized drug doses in clinics and hospitals.
- FDA-approved example: Spritam® (levetiracetam), using binder-jetting with a highly porous structure for rapid dissolution—helpful for individuals with difficulty swallowing.
- Core methods: fused deposition modeling (FDM), binder jetting, stereolithography (SLA), semi‑solid extrusion.
- Advantages: tailored dosing, multi‑drug “polypills,” improved adherence, reduced waste.
- Limitations: production speed, scalability, cost, quality control, evolving regulation.
- Pilot programs and regulatory developments suggest a transformative future in mainstream healthcare.
From Sci‑Fi to Hospital Reality
Imagine a hospital pharmacy where a health professional enters a prescription into software—then, within minutes, a custom‑dose pill is printed just for that user, tailored to their age, weight, and medication needs. No more pill-splitting, complicated schedules, or missed doses. This is not a distant dream—Spritam®, approved by the U.S. Food and Drug Administration (FDA) in 2015, became the first 3D‑printed medicine available to the public, signaling that on‑demand manufacturing in healthcare is possible (FDA, 2015).
Why This Matters for Healthcare
Traditional pharmaceutical manufacturing is built for mass production: millions of identical pills in fixed doses. While efficient, this model leaves little room for personalization. Children, older adults, and users with multiple prescriptions often struggle to take medicines as prescribed—whether due to swallowing difficulty, inconvenient pill sizes, or dosing inflexibility (Pharma Excipients, 2025). 3D printing offers a solution by enabling dose-by-dose customization and even combining several medications into a single tablet (Aprecia, 2024).
The Current Pain Points in Medication
For many users, the problem is not access to medicine—it’s taking it correctly. Fixed-dose tablets may not match the optimal therapeutic dose for every individual. Those with swallowing difficulties face a daily challenge, sometimes resorting to crushing pills, which can alter drug release and efficacy (MDPI, 2024). Polypharmacy—when multiple medications are prescribed—further complicates adherence, increasing the likelihood of missed or incorrect doses (ScienceDirect, 2024).
How 3D Printing Creates a Pill
3D printing in pharmaceuticals uses several main techniques:
- Binder Jetting – A drug-containing powder is bound together layer‑by‑layer using a liquid binding agent. This method, used in Spritam®, produces a porous tablet that dissolves quickly in small amounts of liquid (FDA, 2015).
- Fused Deposition Modeling (FDM) – Drug-loaded polymer filament is extruded under heat, allowing for precise control over dose, shape, and drug release profile (MDPI, 2024).
- Stereolithography (SLA) – Light-sensitive resin infused with drug molecules is cured layer-by-layer using a laser, ideal for heat‑sensitive compounds (ScienceDirect, 2018).
- Semi‑Solid Extrusion (SSE) – Paste-like formulations are extruded at low temperatures, suitable for drugs unstable under heat (MDPI, 2024).
The choice of method depends on the drug’s stability, desired release rate, and the printing environment. Pharmaceutical-grade polymers, hydrogels, and excipients are carefully selected to ensure stability and predictable drug release (Pharma Excipients, 2025).
Where It’s Already in Action
Beyond Spritam®, hospitals in Spain and the UK have piloted 3D printing for personalized cancer therapy tablets and pediatric formulations. These projects demonstrated that point-of-care production can match the bioavailability of conventionally manufactured drugs while improving user acceptability (Hospital Pharmacy Europe, 2024). Research labs are also leveraging 3D printing to create multi-drug “polypills” for cardiovascular disease, combining several active ingredients into one daily tablet (MDPI, 2024).
Regulatory & Safety Hurdles
While the FDA’s approval of Spritam® established a precedent, most health authorities are still developing detailed guidelines for 3D printed medicines, especially those produced on-site at hospitals or pharmacies (FDA, 2023). Regulatory priorities include ensuring batch consistency, preventing counterfeit production, and defining intellectual property protections (Pharma Excipients, 2025). The European Medicines Agency (EMA) is similarly evaluating frameworks to integrate point-of-care 3D printing into the regulated supply chain (EMA, 2024).
The Promise and the Pitfalls
| Potential Benefits | Current Limitations |
|---|---|
| Personalized dosing matched to user needs | Slower production than mass manufacturing |
| Multi‑drug “polypills” to simplify regimens | High equipment and training costs |
| Improved swallowability and adherence | Regulatory uncertainty for point-of-care printing |
| Reduced waste and better inventory management | Need for specialized materials and drug‑loaded feedstock |
Spotlight: Spritam® Case Study
Spritam® (levetiracetam) uses Aprecia’s ZipDose® binder‑jetting process to produce a tablet that dissolves in seconds with a sip of liquid. Designed for those with swallowing challenges, it delivers precise dosing and matches the bioavailability of conventional forms (FDA, 2015). Its approval demonstrated that 3D printed medicines could meet safety, efficacy, and manufacturing quality standards.
What’s Next for 3D Printed Medicines
The next wave of innovation includes AI‑guided tablet design to optimize drug release, biodegradable implants for sustained therapy, and scaled hospital networks capable of producing personalized doses in‑house (Pharma Excipients, 2025). Multi‑drug printing could reduce pill burden for chronic disease management, while genomic data integration might allow ultra‑personalized therapies tailored to an individual’s metabolic profile (Nature, 2024).
Moving Forward Responsibly
For health professionals and pharmaceutical companies, the key is balancing innovation with safety. Hospitals exploring 3D printing will need robust quality-control systems, regulatory compliance, and trained personnel. Pharmaceutical stakeholders may find competitive advantage in partnerships that accelerate safe adoption. As the technology matures, the ability to produce personalized, on-demand medicines could fundamentally change how therapies are delivered—bringing us closer to precision healthcare for all.
Der Artikel stellt in keiner Weise eine medizinische Beratung dar. Bitte konsultieren Sie einen zugelassenen Arzt, bevor Sie eine Behandlung beginnen. Diese Website kann Provisionen für die in diesem Artikel erwähnten Links oder Produkte erhalten.
Quellen
- FDA. “FDA Approves the First 3D Printed Drug Product.” 2015. https://www.fda.gov/media/125479/download
- Pharma Excipients. “3D Printing Medicines: Advances and Challenges.” 2025. https://www.pharmaexcipients.com/news/3d-printing-medicines
- MDPI. “3D Printing of Pharmaceuticals: Recent Advances.” Pharmaceutics, 2024. https://www.mdpi.com/1999-4923/16/10/1285
- ScienceDirect. “3D Printing of Pharmaceuticals: State of the Art.” 2018. https://www.sciencedirect.com/science/article/pii/S0165614718300440
- Hospital Pharmacy Europe. “3D Printing and Personalised Medicines.” 2024. https://hospitalpharmacyeurope.com/in-depth/views/3d-printing-and-personalised-medicines-embracing-innovative-technologies
- Aprecia Pharmaceuticals. “ZipDose Technology Overview.” 2024. https://aprecia.com/resources/press
- European Medicines Agency. “Innovation in Pharmaceutical Manufacturing.” 2024. https://www.ema.europa.eu/en
- Nature. “Clinical Applications of 3D Printed Pharmaceuticals.” 2024. https://www.nature.com/articles/s44222-024-00217-x
Last Updated on August 6, 2025
German 
English